Back to Search

CASEY SUMNER, PHARM.D.

PHARM.D.

Pharmacist

NPI: 1245830934Individual

Specialties, Licenses & Credentials

PharmacistPrimary

Pharmacist

Code: 183500000X

2006031388(MO)17604(AL)

Research & Publications (20)

Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice.
PMID 19477958·Hum Mol Genet·2009
7-preclinical
Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study.
PMID 19318988·J Am Acad Child Adolesc Psychiatry·2009
8-other
Factors affecting the selectivity of the oxidation of methyl p-toluate by cobalt(III).
PMID 18225893·Inorg Chem·2008
8-other
Molecular mechanisms of spinal muscular atrophy.
PMID 17761653·J Child Neurol·2007
6-review
Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.
PMID 17712235·J Am Acad Child Adolesc Psychiatry·2007
2-rct
Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis.
PMID 17201614·J Child Adolesc Psychopharmacol·2006
2-rct
SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials.
PMID 16481599·Neurology·2006
8-other
Therapeutics development for spinal muscular atrophy.
PMID 16554261·NeuroRx·2006
6-review
Valproic acid increases SMN levels in spinal muscular atrophy patient cells.
PMID 14595654·Ann Neurol·2003
4-observational
The spectrum of neuropathy in diabetes and impaired glucose tolerance.
PMID 12525727·Neurology·2003
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
1930 PLEASANT RIDGE LOOP
SYLACAUGA, AL 35150

Quick Facts

NPI
1245830934
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
2
Locations
1
Publications
20

Are you this provider?

Claim Your Profile